tradmap

LH Financials Labcorp

15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →

Growth & profitability

  • Revenue has declined 0.0% per year over the past 5 years.
  • Net income has grown slower than revenue (-10.8% vs -0.0% per year).
  • Operating margin has contracted, at 9.9% in the latest year.
  • Free cash flow has declined 7.2% per year over the past 5 years.

Financial health

  • Total debt ($5.6B) exceeds cash ($532M); net debt is $5.1B.
  • Total debt has grown in line with revenue (0.6% vs -0.0% per year).
  • Operating income covered interest expense 6.2× in the latest year, down from 12× 5 years ago.
  • Total debt is 2.7× EBITDA.

Shareholder returns

  • Dividends have been paid for 4 consecutive years, consuming 27.4% of earnings and 20.0% of free cash flow.
  • The dividend has grown 7.2% per year over the past 5 years.
Revenue & net income
$0 $7B $14B 2012 2013 2015 2017 2019 2021 2023 2025
RevenueNet income
Margins (gross / operating / net)
0% 19% 38% 2012 2013 2015 2017 2019 2021 2023 2025
GrossOperatingNet
Free cash flow (CFO − capex)
$0 $1B $3B 2012 2013 2015 2017 2019 2021 2023 2025
Free cash flow
Cash vs total debt
$0 $3B $7B 2012 2013 2015 2017 2019 2021 2023 2025
CashTotal debt
Cash flow: operating / investing / financing
-$4B -$405M $3B $0 2012 2013 2015 2017 2019 2021 2023 2025
OperatingInvestingFinancing

Key annual figures

FYRevenueNet incomeGross MOp MFCFTotal debtCash
2025 $14.0B $877M 28.8% 9.9% $1.2B $5.6B $532M
2024 $13.0B $746M 27.9% 8.4% $1.1B $6.3B $1.5B
2023 $12.2B $418M 27.7% 6.0% $874M $4.1B $537M
2022 $11.9B $1.3B 31.3% 12.1% $1.5B $5.0B $321M
2021 $13.1B $2.4B 38.0% 23.2% $2.7B $5.4B $1.5B
2020 $14.0B $1.6B 35.4% 17.5% $1.8B $5.4B $1.3B
2019 $11.6B $824M 28.1% 11.5% $1.0B $6.2B $338M
2018 $11.3B $884M 28.0% 11.7% $926M $6.0B $427M
2017 $10.3B $1.2B 30.0% 12.7% $1.2B $6.7B $317M
2016 $9.6B $712M 29.9% 13.3% $918M $5.8B $434M
2015 $8.7B $438M 33.4% 11.5% $727M $6.4B $716M
2014 $6.0B $511M 36.6% 15.1% $536M $3.0B $580M
2013 $5.8B $574M 38.3% 17.1% $617M $3.0B $404M
2013 $148M $2.6B $576M
2012 $583M $668M $2.2B $404M

Valuation over time

How the market has priced LH against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.

Price / earnings (P/E)
0.0 23.7 47.3 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/E
Price / sales (P/S)
0.0 0.9 1.8 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
P/S
Dividend yield (%)
0.0 0.8 1.6 Mar '23 Aug '23 Jan '24 Jun '24 Nov '24 Apr '25 Sep '25 Feb '26
Dividend yield %

Frequently asked questions

Is LH growing its revenue and profit?

Over the past 5 years, Labcorp's revenue has declined 0.0% per year, and net income declined 10.8% per year. These are computed facts, not advice.

How much debt does LH have?

As of FY2025, Labcorp reported $5.6B of total debt against $532M of cash; operating income covered interest expense 6.2×.

What is LH's profit margin?

In FY2025, gross margin was 28.8%, operating margin 9.9%, and net margin 6.3%.

What is LH's P/E ratio?

As of Jun '26, Labcorp traded at a price-to-earnings ratio of about 24.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.

Where does this data come from?

All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.

Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.